Paroxysmal nocturnal haemoglobinuria

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
2 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Complement inhibitor (C5) 2 substances
Phase III: 4

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

4 trials
  • Alexion Pharmaceuticals Inc. Commercial
    DANICOPAN; ECULIZUMAB; RAVULIZUMAB
    2023-504867-18-00 6 countries 2022 n=25 Orphan
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN
    2022-502148-10-00 4 countries 2023 n=25 Orphan
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN
    2023-509843-28-00 7 countries 2021 n=86 Orphan
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN HYDROCHLORIDE
    2024-515926-10-00 5 countries 2025 n=5 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 3 Phase III 1
Alexion Pharmaceuticals Inc. Commercial 1 Phase III 0
New trials by year
2021
1
2022
1
2023
1
2025
1
← All indication landscapes